131 related articles for article (PubMed ID: 18980272)
1. Using the International Gaucher Disease Registry data: can we devise a virtuous circle for treated patients?
Elstein D; Zimran A
Am J Hematol; 2008 Dec; 83(12):887-9. PubMed ID: 18980272
[No Abstract] [Full Text] [Related]
2. [Osteoarticular manifestations of Gaucher disease in adults: pathophysiology and treatment].
Hachulla E; Javier RM
Rev Med Interne; 2007 Oct; 28 Suppl 2():S180-2. PubMed ID: 18228685
[No Abstract] [Full Text] [Related]
3. [Gaucher disease with multiple bone necrosis treated by enzyme replacement therapy and pamidronate].
Abe M; Minoguchi M; Jinbo J; Kikuchi Y; Chiba A; Shibata Y; Kogo Y
Nihon Naika Gakkai Zasshi; 2004 Nov; 93(11):2421-3. PubMed ID: 15624481
[No Abstract] [Full Text] [Related]
4. Enzyme replacement therapy for mild patients with Gaucher disease.
Zimran A; Ilan Y; Elstein D
Am J Hematol; 2009 Apr; 84(4):202-4. PubMed ID: 19229987
[No Abstract] [Full Text] [Related]
5. Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations.
Charrow J; Andersson HC; Kaplan P; Kolodny EH; Mistry P; Pastores G; Prakash-Cheng A; Rosenbloom BE; Scott CR; Wappner RS; Weinreb NJ
J Pediatr; 2004 Jan; 144(1):112-20. PubMed ID: 14722528
[No Abstract] [Full Text] [Related]
6. Gaucher disease: resetting the clinical and scientific agenda.
Mistry PK; Weinreb NJ; Brady RO; Grabowski GA
Am J Hematol; 2009 Apr; 84(4):205-7. PubMed ID: 19296473
[No Abstract] [Full Text] [Related]
7. Histologic findings of femoral heads from patients with Gaucher disease treated with enzyme replacement.
Lebel E; Elstein D; Peleg A; Reinus C; Zimran A; Amir G
Am J Clin Pathol; 2013 Jul; 140(1):91-6. PubMed ID: 23765538
[TBL] [Abstract][Full Text] [Related]
8. Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis.
Mistry PK; Deegan P; Vellodi A; Cole JA; Yeh M; Weinreb NJ
Br J Haematol; 2009 Nov; 147(4):561-70. PubMed ID: 19732054
[TBL] [Abstract][Full Text] [Related]
9. Cholangiocarcinoma occurring in a patient with type 1 Gaucher disease treated with velaglucerase alfa enzyme replacement therapy: First case report.
Holubar J; Bres V; Costes-Martineau V; Pers YM
Blood Cells Mol Dis; 2018 Feb; 68():112-114. PubMed ID: 28559130
[No Abstract] [Full Text] [Related]
10. Pulmonary arterial hypertension with plexogenic arteriopathy in enzyme-substituted Gaucher disease.
den Bakker MA; Grünberg K; Boonstra A; van Hal PT; Hollak CE
Histopathology; 2012 Aug; 61(2):324-6. PubMed ID: 22690977
[No Abstract] [Full Text] [Related]
11. Osteonecrosis in a patient with Gaucher's disease treated with enzyme replacement.
Lebel E; Elstein D; Hain D; Hadas-Halpern I; Zimran A; Itzchaki M
Isr Med Assoc J; 2003 Aug; 5(8):595-6. PubMed ID: 12929302
[No Abstract] [Full Text] [Related]
12. Competing for the treasure in exceptions.
Cox TM
Am J Hematol; 2013 Mar; 88(3):163-5. PubMed ID: 23400870
[No Abstract] [Full Text] [Related]
13. Commentary: low-dose high-frequency enzyme replacement therapy prevents fractures without complete suppression of painful bone crises in patients with severe juvenile onset type I Gaucher disease.
Elstein D; Abrahamov A; Itzchaki M; Zimran A
Blood Cells Mol Dis; 1998 Sep; 24(3):303-5; discussion 306-8. PubMed ID: 10087988
[No Abstract] [Full Text] [Related]
14. A case report of secondary autograft failure due to Gaucher disease.
Carreiro J; Balwani M; Grosskreutz C; Isola L; Malone A; Scigliano E; Osman K
Am J Hematol; 2008 Dec; 83(12):937. PubMed ID: 18803277
[No Abstract] [Full Text] [Related]
15. [Gaucher's disease: a second drug is now available].
Stirnemann J
Rev Prat; 2003 Sep; 53(13):1401-2. PubMed ID: 14558259
[No Abstract] [Full Text] [Related]
16. Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: a study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
Khan A; Hangartner T; Weinreb NJ; Taylor JS; Mistry PK
J Bone Miner Res; 2012 Aug; 27(8):1839-48. PubMed ID: 22692814
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic goals in Gaucher disease.
Mistry P; Germain DP
Rev Med Interne; 2006 Mar; 27 Suppl 1():S30-8. PubMed ID: 16644400
[TBL] [Abstract][Full Text] [Related]
18. Velaglucerase (Vpriv) for Gaucher's disease.
Med Lett Drugs Ther; 2010 May; 52(1337):36. PubMed ID: 20508578
[No Abstract] [Full Text] [Related]
19. Pulmonary hypertension in type 1 Gaucher's disease. Comité d'Evaluation du Traitement de la Maladie de Gaucher.
Belmatoug N; Launay O; Carbon C
Lancet; 1998 Jul; 352(9123):240. PubMed ID: 9683246
[No Abstract] [Full Text] [Related]
20. [Organization of Gaucher disease management in France].
Stirnemann J; de Villemeur TB; Belmatoug N
Rev Med Interne; 2007 Oct; 28 Suppl 2():S198-201. PubMed ID: 18228688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
